

CONTENTS

Preface xiii

INTRODUCTION 1

Biotechnology Law	1
Scientists and the Study of Biotechnology Law	3
<i>Who Is a Scientist for the Purpose of This Book?</i>	3
<i>Why Should Scientists Learn About Biotechnology Law?</i>	3
<i>How Should They Learn About It?</i>	4
<i>What This Book Covers</i>	5
<i>How This Book Covers It</i>	6
Biotechnology Law in the Scheme of U.S. Law	7
<i>Three Branches and a Constitution</i>	8
<i>Statutes, Rules, and Common Law</i>	8
<i>Patent Law</i>	9
<i>Regulatory Law</i>	9
<i>Contract Law</i>	10

SECTION I: PATENT LAW

1. THE PATENT AS A NEGATIVE RIGHT AND THE CLAIM AS ITS BUSINESS END 13

Territoriality and a Quid Pro Quo	13
The Anatomy of a Patent	14

Patent Claims	15
<i>Claim Structure</i>	16
<i>Claim Scope and Language</i>	18
The Patent as a Negative Right: A Counterintuitive Notion	21

2. CONSTRUING THE PATENT CLAIM 24

3. THE PATENTABLE INVENTION 29

Patent-Eligible Subject Matter	29
Utility	32
Novelty	36
Nonobviousness	42

4. THE PATENT DOCUMENT'S ROLE IN SUPPORTING A CLAIMED INVENTION 49

Written Description	49
Enablement	52
Definiteness	55

5. THE LONG ROAD TO GETTING A PATENT 57

The Scientific Event	58
Defining the Invention	58
Determining Inventorship	60
Preparing and Filing a Patent Application	60
<i>What Kind of Patent Application Should Be Filed?</i>	61
<i>Provisional Applications</i>	61
<i>Nonprovisional Applications</i>	61
<i>PCT Applications</i>	62
<i>Tactical Considerations</i>	63
<i>Where Should the Application Be Filed?</i>	64
Examining the Patent Application	65
<i>Restriction Practice: One Invention per Patent</i>	65

Substantively Examining the Patent Application 67
Allowing the Application and Issuing the Patent 69

6. LENGTHENING AND SHORTENING A PATENT'S TERM 70

Extending a Patent's Term 70
Adjusting a Patent's Term 71
 Double Patenting 74
 Statutory Double Patenting 75
 Obviousness-Type Double Patenting and
 Terminally Disclaiming a Patent's Term 75

7. CONTINUING-APPLICATION PRACTICE AND THE MAKING OF A PATENT FAMILY 78

The Continuing Application Defined 79
 Divisional Applications 79
 Continuation Applications 81
 CIP Applications 83
Strategy and the Making of a Patent Family 87

8. THE MURKY WORLD OF INVENTORSHIP 89

Conception: The Sine Qua Non of Inventorship 89
 If It's Not Conception, It's Not Inventorship 90
 Authorship 91
 Providing a Goal 92
 Performing Experiments 93
 Explaining Technology and Elucidating
 an Invention's Mode of Action 94
 Getting Inventorship Right 95
 Inclusion and Omission 96
 Joint Conception 96
 Agendas 97
Business Consequences of Incorrect Inventorship 98
 Liability for Willfully Omitting an Inventor 99

9. PATENT INFRINGEMENT AND ITS VARIATIONS 101

- Not All Roads Lead to Litigation 101
 - Avoiding Infringement* 101
 - Patent Licensing* 102
- When Patent Infringement Litigation Is the Answer 102
 - What Is Patent Infringement? 103
 - Types of Infringement 105
 - Direct Infringement* 106
 - Inducement to Infringe* 107
 - Contributory Infringement* 108
 - Literal Infringement* 109
 - Infringement Under the Doctrine of Equivalents* 110

10. DEFENSES AND PREEMPTIVE CHALLENGES 116

- Defenses to an Infringement Suit 116
- Infringement Assertions Generally 116
 - Noninfringement 117
 - Invalidity 119
 - Unenforceability 124
 - Duty of Candor* 125
 - Inequitable Conduct and Patent Unenforceability* 125
- Challenging a Patent Preemptively 126
 - The Declaratory Judgment Action* 126
 - The Inter Partes Review* 128

11. PATENT OPINIONS 129

- What Is a Patent Opinion? 129
- Noninfringement Opinions 130
- Infringement Opinions 133
 - Invalidity Opinions 135
 - Validity Opinions 137
- Freedom-to-Operate Opinions 138
- Risks of Relying on a Patent Opinion 140
- Benefits of Relying on a Patent Opinion 140

12. THE PATENT PORTFOLIO 142

- The Patent Portfolio Defined 142
- Managing a Patent Portfolio 145
- Valuing a Patent Portfolio 150

**13. THE INTERPLAY BETWEEN TRADE SECRETS
AND PATENTS 151**

- The Trade Secret Defined 151
- Patent or Trade Secret? 154

SECTION II: REGULATORY LAW**14. THE INNOVATOR DRUG:
FROM DEVELOPMENT TO APPROVAL 163**

- Small-Molecule Drugs 164
 - Research and Preclinical Development* 164
 - The Investigational New Drug Application* 166
 - Testing a Drug Candidate in Humans* 167
 - The Phase 1 Clinical Trial* 167
 - The Phase 2 Clinical Trial* 170
 - The Phase 3 Clinical Trial* 170
 - Clinical Trial Variations* 172
 - FDA Approval and the New Drug Application* 174
 - Postapproval Studies and Monitoring* 175
 - New Indications for Approved Drugs* 175
- Biologic Drugs 176

15. GENERIC DRUGS 180

- The Early Days and the Need for Change 181
- The Hatch–Waxman Act and Today’s Generic Drug Industry 182
 - Rewarding Innovators 183
 - Patent-Term Extension* 183

<i>Regulatory Exclusivity</i>	184
<i>NCE Exclusivity</i>	184
<i>CI Exclusivity</i>	185
<i>Orphan Drug Exclusivity</i>	187
<i>Pediatric Exclusivity</i>	187
<i>The Interplay Between Regulatory and Patent Exclusivities</i>	188
<i>The Orange Book</i>	191
<i>Rewarding Generic Competitors</i>	191
<i>The ANDA</i>	192
<i>The §505(b)(2) Application</i>	193
<i>Patent Certification</i>	195
<i>Skinny Labeling</i>	196
<i>Safe Harbor</i>	198
<i>Hatch–Waxman Litigation</i>	199
<i>ANDA Exclusivity</i>	201
<i>Prolonging the Innovator’s Market Dominance</i>	204
<i>Evergreening</i>	204
<i>Trademark Protection</i>	206

16. BIOSIMILARS 207

<i>What Price Biologics?</i>	208
<i>Two Realms</i>	208
<i>European Biosimilars and Sober Expectations in the United States</i>	209
<i>The BPCI Act</i>	210
<i>Rewarding Biosimilar Competitors</i>	211
<i>Biosimilarity</i>	212
<i>Interchangeability</i>	214
<i>Exclusivity for First Licensed Interchangeable Biologics</i>	215
<i>Rewarding Biologic Innovators</i>	215
<i>Innovator Exclusivity</i>	215
<i>Is Twelve Years Too Long?</i>	217
<i>The Patent Dance</i>	217
<i>Biobetters: A Third Way</i>	219

SECTION III: CONTRACT LAW

17. THE CONTRACT: AN ENFORCEABLE PROMISE 225

Elements of an Enforceable Contract 226

Lawful Purpose 226

Legal Capacity 227

Offer and Acceptance 229

Mutual Consideration 231

Breach 232

Remedies 233

Expectation 233

Reliance 234

Restitution 235

The Anatomy of a Contract 236

Recitals 237

Definitions 237

Control 238

Ownership 238

Patents 238

Payments 239

Confidentiality 239

Warranties and Indemnification 239

Termination 240

Principles of Note 240

People Come and Go 240

The Devil Is in the Details 241

18. BIOTECHNOLOGY AGREEMENTS 242

Confidentiality Agreements 243

Material Transfer Agreements 248

Patent License Agreements 252

The Grant Clause 254

The Concept of Exclusivity 254

Exclusive Licenses 255

<i>Nonexclusive Licenses</i>	256
<i>Field of Use</i>	259
<i>Territory</i>	264
<i>License Payments</i>	266
<i>Up-Front and Milestone Payments</i>	268
<i>Royalty Payments</i>	269
<i>Collaboration Agreements</i>	270
<i>Defining the Collaboration</i>	271
<i>Intellectual Property</i>	275
<i>Collaboration Costs and Profits</i>	278
<i>Collaboration Payments</i>	279
<i>Termination</i>	280

ACKNOWLEDGMENTS 283

<i>Further Reading</i>	285
<i>Glossary of Legal Acronyms and Abbreviations</i>	295
<i>Index</i>	297